Proceedings · Session S-820 · filed November 17, 2026
Translational ScienceSession paper
Takeda Launches First Orexin Agonist for Narcolepsy Type 1 in US
DEA Schedule IV placement of oveporexton on November 12, 2026 clears Takeda to launch the first orexin agonist for adults with narcolepsy type 1 in the US.
By Priya Raman3 min read544 words
Summary
- DEA placed oveporexton in Schedule IV on November 12, 2026, via an interim final rule effective immediately.
- FDA approved ORZEYFUL in August 2026; public comment on the DEA rule runs through December 14, 2026.
- Abuse-potential study found drug-liking scores not statistically different from Schedule IV phentermine.
- Distribution runs exclusively through Accredo Specialty Pharmacy, part of Evernorth Health Services.
- Most common side effects: insomnia, urinary urgency, urinary frequency, excessive saliva.
The US Drug Enforcement Administration placed oveporexton in Schedule IV of the Controlled Substances Act on November 12, 2026, clearing the way for Takeda to launch ORZEYFUL, the first and only orexin agonist available to adults with narcolepsy type 1 in the United States. The interim final rule took effect immediately and remains open for public comment through December 14, 2026.
The FDA approved ORZEYFUL in August 2026, pending controlled-substance classification. That administrative gap of roughly three months between approval and launch now determines the practical start of prescribing, and the DEA's eight-factor review, conducted with the Department of Health and Human Services, framed the scheduling decision in concrete pharmacological terms. In a human abuse-potential study, supratherapeutic doses of oveporexton produced drug-liking scores not statistically different from those of phentermine, the Schedule IV stimulant. The agency concluded the drug poses a low risk of physical or psychological dependence.
What does the drug target?
Narcolepsy type 1 is a rare, chronic neurological disease driven by a loss of orexin. Its clinical profile includes excessive daytime sleepiness, cataplexy — sudden loss of muscle tone — cognitive symptoms, and disrupted nighttime sleep. Existing therapies manage symptoms; ORZEYFUL works differently. It is an oral orexin receptor 2 (OX2R) agonist that selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency. By activating these receptors, the medication promotes wakefulness and reduces abnormal REM-sleep-like phenomena, including cataplexy.
For sleep medicine clinics, the mechanism shifts the treatment conversation toward cause rather than symptom control. Emmanuel Mignot, MD, PhD, principal US investigator in the ORZEYFUL phase 3 program, framed the change in practice terms: "Clinical trials showed ORZEYFUL improved the full range of symptoms, and now we can bring those results into real-world practice." He added: "Using ORZEYFUL to target the underlying cause of narcolepsy type 1 is a welcome and exciting development in sleep medicine. I can now start a new conversation with my patients about their symptoms and how using this new treatment approach may make a real difference for them."
How will patients access it?
The medication will be dispensed across the US through Accredo Specialty Pharmacy, part of Evernorth Health Services, rather than through general retail channels — a distribution decision that shapes payer and prior-authorization workflows for prescribing clinics. Takeda says access support is its immediate priority. Rhonda Pacheco, president of Takeda's US business unit, said in a release: "We work for decades toward the defining moments that have the potential to make a real difference for patients." She continued: "Bringing ORZEYFUL, a first-in-class medicine, to people living with narcolepsy type 1 in the US is one of those moments. We're incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed ORZEYFUL."
The prescribing information lists the most common side effects as insomnia, urinary urgency, urinary frequency, and excessive saliva. Takeda has also launched the drug simultaneously in Japan and China, giving the molecule a three-market commercial footprint in its first year.
Prescribers and patients now enter the real-world phase, where the phase 3 findings on the full NT1 symptom range will meet the demands of long-term tolerability, adherence and reimbursement data.
via sleepreviewmag.com (Source)
Filed under
- narcolepsy-type-1
- orexin-agonists
- oveporexton
- orzeyful
- dea-scheduling
More from Priya Raman
Show full bio
Staff writer covering money, funding and market shifts around research and development at Hypothesis Wire.
281 articles
References
- FDA Breakthrough Status for Daridorexant Opens Pediatric Insomnia Path
- FDA Proposes First Drug-to-Supplement Path That Could Reach CBD
- Carnyx Targets 2027 IND Filing for Oral Sleep Candidate CNYX-005
- Wrist Actigraphy Algorithm Quantifies Narcolepsy Burden in Nap-Free Days
- FDA Opens Ibogaine Trial Docket; AstraZeneca Unveils $1B Cambridge R&D Center